ClinConnect ClinConnect Logo
Search / Trial NCT03626506

Spironolactone Versus Indapamide in Obese and Hypertensive Patients

Launched by PEKING UNIVERSITY THIRD HOSPITAL · Aug 3, 2018

Trial Information

Current as of August 02, 2025

Unknown status

Keywords

Spironolactone Indapamide Obesity Hypertension Target Organ Damage

ClinConnect Summary

Thiazide diuretics have been widely used for the management of essential hypertension, especially in patients with salt-sensitive hypertension. Most recent guidelines continue to recommend thiazide diuretics as first-line agents for all patients with hypertension in spite of the potential metabolic side effects such as hypokalemia, hypertriglyceridemia, impaired glucose tolerance and increases in serum cholesterol and uric acid. However, mineralocorticoid receptor antagonists (MRAs), such as spironolactone or eplerenone, are mainly recommended to be used in patients with resistant hypertens...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Patients with essential hypertension aged between 18-80years
  • 2. Office systolic blood pressure (SBP)≥140mmHg and \<180mmHg without treatment or on one antihypertensive drug or SBP\<140mmHg on two antihypertensive drugs
  • 3. Waist circumference ≥90cm for males, ≥ 80cm for females
  • Exclusion Criteria:
  • 1. Secondary hypertension.
  • 2. Symptomatic congestive heart failure or history of heart failure.
  • 3. History of ischemic stroke, unstable angina or myocardial infarction;
  • 4. Atrial fibrillation
  • 5. Serum creatinine ≥ 2.0mg/dl or eGFR≤ 30 ml/min/1.73 m2
  • 6. Serum K+ ≥ 5.0 mmol/L or ≤3.5 mmol/L

About Peking University Third Hospital

Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.

Locations

Beijing, Beijing, China

Patients applied

0 patients applied

Trial Officials

Wang Guisong, MD

Principal Investigator

Peking University Third Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials